Compare PLBC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBC | EBS |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.7M | 466.9M |
| IPO Year | 2002 | 2006 |
| Metric | PLBC | EBS |
|---|---|---|
| Price | $51.65 | $8.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $57.67 | $12.00 |
| AVG Volume (30 Days) | 23.3K | ★ 616.5K |
| Earning Date | 04-15-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ 1.38 | 0.07 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | $25.59 | $1.29 |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | ★ $37.32 | $116.43 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.70 | $5.62 |
| 52 Week High | $54.58 | $14.06 |
| Indicator | PLBC | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 42.97 |
| Support Level | $50.20 | $7.73 |
| Resistance Level | $52.19 | $8.95 |
| Average True Range (ATR) | 0.89 | 0.52 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 46.08 | 26.23 |
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.